Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide

Semaglutide and tirzepatide are two commonly prescribed glucagon-like peptide-1 (GLP-1) and GLP-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonists used for the treatment of type 2 diabetes and chronic weight management. Allodynia and dysesthesia have been previously reported as effects of semaglutide. This case report adds to the literature on dysesthesia from semaglutide and presents a novel report in a patient taking tirzepatide. This adverse drug reaction occurs in both patients treated for type 2 diabetes and chronic weight management, appears to be dose dependent, and resolves with discontinuation of the drug and may resolve spontaneously after several weeks.